Intestinal targeting of drugs: Rational design approaches and challenges

Current Topics in Medicinal Chemistry

Volumn 13, Issue 6 7, 2013, Pages 776-802

  Filipski, Kevin J ^a   Varma, Manthena V ^a   El Kattan, Ayman F ^a   Ambler, Catherine M ^a   Ruggeri, Roger B ^a   Goosen, Theunis C ^a   Cameron, Kimberly O ^a  

^a PFIZER INC   (United States)

Author keywords

Drug; Gut; Intestine; Non systemic; Prodrug; Soft drug; Targeting; Transporter

Indexed keywords

CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CYCLODEXTRIN; CYTOCHROME P450 ISOENZYME; EZETIMIBE; FIDAXOMICIN; IMIDAZOPYRIDINE DERIVATIVE; LINACLOTIDE; LOPERAMIDE; LOPERAMIDE 1 OXIDE; LUBIPROSTONE; MESALAZINE; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; MONOCARBOXYLATE TRANSPORTER; MORPHINE; NYSTATIN; OLSALAZINE; OMEPRAZOLE; OPIATE ANTAGONIST; ORGANIC ANION TRANSPORTER; OTILONIUM BROMIDE; PINAVERIUM BROMIDE; PRODRUG; RAMOPLANIN; RIFAMYCIN; RIFAXIMIN; ROSUVASTATIN; SALAZOSULFAPYRIDINE; TETRAHYDROLIPSTATIN; UNINDEXED DRUG; VANCOMYCIN;

ACTIVE TRANSPORT; CANDIDIASIS; CHILL; COLON; CONFUSION; CONSTIPATION; CROHN DISEASE; DIARRHEA; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG INHIBITION; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG TARGETING; DUODENUM ULCER; FEVER; HUMAN; INTESTINE; INTESTINE CELL; IRRITABLE COLON; LIPOPHILICITY; MALAISE; META ANALYSIS (TOPIC); NAUSEA; NEUROGENIC BOWEL; NONHUMAN; OBESITY; PH; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; REVIEW; SCLEROSIS; STOMACH ULCER; TACHYCARDIA; TISSUE DISTRIBUTION; ULCERATIVE COLITIS; XEROSTOMIA;

EID: 84878773102     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611313070002     Document Type: Review

References (243)

1. Raschi, E.; Ceccarini, L.; De Ponti, F.; Recanatini, M. hERG-related drug toxicity and models for predicting hERG liability and QT prolongation. Expert Opin. Drug Metab. Toxicol., 2009, 5(9), 1005-1021.
2. Yeung, K.-S.; Meanwell, N.A. Inhibition of hERG channel trafficking: an under-explored mechanism for drug-induced QT prolongation. ChemMedChem, 2008, 3(10), 1501-1502.
3. Hancox, J.C.; McPate, M.J.; El Harchi, A.; Zhang, Y.H. The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol. Ther., 2008, 119(2), 118-132.
4. Sanguinetti, M.C.; Tristani-Firouzi, M. hERG potassium channels and cardiac arrhythmia. Nature, 2006, 440(7083), 463-469.
5. Pfefferkorn, J.A. Muscle-sparing statins: preclinical profiles and future clinical use. Curr. Opin. Investig. Drugs, 2009, 10(3), 245-252.
6. Heuschkel, S.; Goebel, A.; Neubert Reinhard, H.H. Microe-mulsions--modern colloidal carrier for dermal and transdermal drug delivery. J. Pharm. Sci., 2008, 97(2), 603-631.
7. Liu, J.; Hu, W.; Chen, H.; Ni, Q.; Xu, H.; Yang, X. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int. J. Pharm., 2007, 328(2), 191-195.
8. Bodor, N; Buchwald, P. Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J., 2005, 7(4), E820-E833.
9. Salt, A.N.; Plontke, S.K. Principles of local drug delivery to the inner ear. Audiol. Neurootol., 2009,14(6), 350-360.
10. Glossop, PA.; Watson, C.A.L.; Price, DA.; Bunnage, M.E.; Middleton, D.S.; Wood, A.; James, K.; Roberts, D.; Strang, R.S.; Yeadon, M.; Perros-Huguet, C; Clarke, N.P.; Trevethick, M.A.; Machin, I.; Stuart, E.F.; Evans, S.M.; Harrison, A.C.; Fairman, DA.; Agoram, B.; Burrows, J.L.; Feeder, N; Fulton, C.K.; Dillon, B.R.; Entwistle, DA.; Spence, F.J. Inhalation by design: Novel tertiary amine muscarinic M3 receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease. J. Med. Chem., 2011, 54(19), 6888-6904.
11. Ranney, D.F. Drug targeting to the lungs. Biochem. Pharmacol, 1986, 35(7), 1063-1069.
12. Courrier, H.M.; Butz, N; Vandamme, T.F. Pulmonary drug delivery systems: recent developments and prospects. Crit. Rev. Ther. Drug Carrier Syst, 2002,19(4 & 5), 425-498.
13. Friden, M.; Winiwarter, S.; Jerndal, G.; Bengtsson, O.; Wan, H.; Bredberg, U.; Hammarlund-Udenaes, M.; Antonsson, M. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J. Med. Chem., 2009, 52(20), 6233-6243.
14. Hossain, S.; Akaike, T.; Chowdhury, E.H. Current approaches for drug delivery to central nervous system. Curr. Drug Deliv., 2010, 7(5), 389-397.
15. Gabathuler, R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol. Dis., 2010, 37(1), 48-57.
16. Dolman, M.E.M.; Fretz, M.M.; Segers, G.J.W.; Lacombe, M.; Prakash, J.; Storm, G.; Hennink, W.E.; Kok, R.J. Renal targeting of kinase inhibitors. Int. J. Pharm., 2008, 364(2), 249-257.
17. Narang, A.S.; Mahato, R.I. In: Targeted Delivery of Small and Macromolecular Drugs Narang, A.S.; Mahato, R.I.; Eds.; CRC Press: Boca Raton, 2010; pp 351-370.
18. Drieman, J.C.; Thijssen, H.H.W.; Struyker-Boudier, H.A.J. Renal selective N-acetyl-y-glutamyl prodrugs. II. Carrier-mediated transport and intracellular conversion as determinants in the renal selectivity of N-acetyl-y-glutamyl sulfamethoxazole. J. Pharmacol. Exp. Ther., 1990, 252(3), 1255-1260.
19. Lachance, N; Guiral, S.; Huang, Z.; Leclerc, J.-P.; Li, C.S.; Oballa, R.M.; Ramtohul, Y.K.; Wang, H.; Wu, J.; Zhang, L. Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series. Bioorg. Med. Chem. Lett, 2012, 22(1), 623-627.
20. Oballa, R.M.; Belair, L.; Black, W.C.; Bleasby, K.; Chan, C.C.; Desroches, C; Du, X.; Gordon, R.; Guay, J.; Guiral, S.; Hafey, M.J.; Hamelin, E.; Huang, Z.; Kennedy, B.; Lachance, N; Landry, F.; Li, C.S.; Mancini, J.; Normandin, D.; Pocai, A.; Powell, DA.; Ramtohul, Y.K.; Skorey, K.; Sorensen, D.; Sturkenboom, W.; Styhler, A.; Waddleton, D.M.; Wang, H.; Wong, S.; Xu, L.; Zhang, L. Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. J. Med. Chem., 2011, 54(14), 5082-5096.
21. Powell, DA.; Black, W.C.; Bleasby, K.; Chan, C.-C; Deschenes, D.; Gagnon, M.; Gordon, R.; Guay, J.; Guiral, S.; Hafey, M.J.; Huang, Z.; Isabel, E.; Leblanc, Y.; Styhler, A.; Xu, L.-J.; Zhang, L.; Oballa, R.M. Nicotinic acids: Liver-targeted SCD inhibitors with preclinical anti-diabetic efficacy. Bioorg. Med. Chem. Lett, 2011, 21(24), 7281-7286.
22. Ramtohul, Y.K.; Powell, D.; Leclerc, J.-P.; Leger, S.; Oballa, R.; Black, C; Isabel, E.; Li, C.S.; Crane, S.; Robichaud, J.; Guay, J.; Guiral, S.; Zhang, L.; Huang, Z. Bicyclic heteroaryl inhibitors of stearoyl-CoA desaturase: From systemic to liver-targeting inhibitors. Bioorg. Med. Chem. Lett, 2011, 21(19), 5692-5696.
23. Pfefferkorn, J.A.; Guzman-Perez, A.; Litchfield, J.; Aiello, R.; Treadway, J.L.; Pettersen, J.; Minich, M.L.; Filipski, K.J.; Jones, C.S.; Tu, M.; Aspnes, G.; Risley, H.; Bian, J.; Stevens, B.D.; Bourassa, P.; DAquila, T.; Baker, L.; Barucci, N; Robertson, A.S.; Bourbonais, F.; Derksen, D.R.; MacDougall, M.; Cabrera, O.; Chen, J.; Lapworth, A.L.; Landro, J.A.; Zavadoski, W.J.; Atkinson, K.; Haddish-Berhane, N; Tan, B.; Yao, L.; Kosa, R.E.; Varma, M.V.; Feng, B.; Duignan, D.B.; El-Kattan, A.; Murdande, S.; Liu, S.; Ammirati, M.; Knafels, J.; DaSilva-Jardine, P.; Sweet, L.; Liras, S.; Rolph, T.P. Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating Type 2 diabetes mellitus. J. Med. Chem., 2012, 55(3), 1318-1333.
24. Pfefferkorn, J.A.; Litchfield, J.; Hutchings, R.; Cheng, X.-M.; Larsen, S.D.; Auerbach, B.; Bush, M.R.; Lee, C.; Erasga, N.; Bowles, D.M.; Boyles, D.C.; Lu, G.; Sekerke, C.; Askew, V.; Hanselman, J.C.; Dillon, L.; Lin, Z.; Robertson, A.; Olsen, K.; Boustany, C.; Atkinson, K.; Goosen, T.C.; Sahasrabudhe, V.; Chupka, J.; Duignan, D.B.; Feng, B.; Scialis, R.; Kimoto, E.; Bi, Y.-A.; Lai, Y.; El-Kattan, A.; Bakker-Arkema, R.; Barclay, P.; Kindt, E.; Le, V.; Mandema, J.W.; Milad, M.; Tait, B.D.; Kennedy, R.; Trivedi, B.K.; Kowala, M. Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: A bench-to-bedside case study on tissue selective drug distribution. Bioorg. Med. Chem. Lett., 2010, 21(9), 2725-2731.
25. Dirksen, C.; Jorgensen, N.B.; Bojsen-Moller, K.N.; Jacobsen, S.H.; Hansen, D.L.; Worm, D.; Holst, J.J.; Madsbad, S. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia, 2012, 55(7), 1890-1901.
26. Cummings, D.E. Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery. Int. J. Obes. (Lond.), 2009, 33 Suppl 1, S33-40.
27. Nicholson, J.K.; Holmes, E.; Kinross, J.; Burcelin, R.; Gibson, G.; Jia, W.; Pettersson, S. Host-gut microbiota metabolic interactions. Science, 2012, 336(6086), 1262-1267.
28. Greiner, T.; Backhed, F. Effects of the gut microbiota on obesity and glucose homeostasis. Trends Endocrinol. Metab., 2011, 22(4), 117-123.
29. Murphy, S.F.; Kwon, J.H.; Boone, D.L. Novel players in inflammatory bowel disease pathogenesis. Curr. Gastroenterol. Rep., 2012, 14(2), 146-152.
30. Maccaferri, S.; Biagi, E.; Brigidi, P. Metagenomics: key to human gut microbiota. Dig. Dis., 2011, 29(6), 525-530.
31. Tilg, H.; Kaser, A. Gut microbiome, obesity, and metabolic dysfunction. J. Clin. Invest., 2011, 121, 2126-2132.
32. Wilding, I.R.; Davis, S.S.; O'Hagan, D.T. Targeting of drugs and vaccines to the gut. Pharmacol. Ther., 1994, 62(1-2), 97-124.
33. Charmot, D. Non-systemic drugs: a critical review. Curr. Pharm. Des., 2012, 18(10), 1434-1445.
34. Curran, M.P.; Robinson, D.M. Lanthanum carbonate. A review of its use in lowering serum phosphate in patients with end-stage renal disease. Drugs, 2009, 69(16), 2329-2349.
35. Pennick, M.; Dennis, K.; Damment, S.J.P. Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. J. Clin. Pharmacol., 2006, 46(7), 738-746.
36. Damment, S.J.P.; Pennick, M. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. Clin. Pharmacokinet., 2008, 47(9), 553-563.
37. Biggar, P.; Ketteler, M. Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III-V). Expert Opin. Pharmacother., 2010, 11(16), 2739-2750.
38. Ehrenpreis Eli, D.; Chang, D.; Eichenwald, E. Pharmacotherapy for fecal incontinence: a review. Dis. Colon Rectum, 2007, 50(5), 641-649.
39. Bijkerk, C.J.; Muris, J.W.M.; Knottnerus, J.A.; Hoes, A.W.; de Wit, N.J. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther., 2004, 19(3), 245-251.
40. Hurst, S.; Loi, C.M.; Brodfuehrer, J.; El-Kattan, A. Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. Expert Opin. Drug Metab. Toxicol., 2007, 3(4), 469-489.
41. Thelen, K.; Dressman, J.B. Cytochrome P450-mediated metabolism in the human gut wall. J. Pharm. Pharmacol., 2009, 61(5), 541-558.
42. th Ed.; Pearson Benjamin Cummings: San Francisco, 2004.
43. van De Waterbeemd, H.; Smith, D.A.; Beaumont, K.; Walker, D.K. Property-based design: optimization of drug absorption and pharmacokinetics. J. Med. Chem., 2001, 44(9), 1313-1333.
44. Knipp, G.T.; Ho, N.F.; Barsuhn, C.L.; Borchardt, R.T. Paracellular diffusion in Caco-2 cell monolayers: effect of perturbation on the transport of hydrophilic compounds that vary in charge and size. J. Pharm. Sci., 1997, 86(10), 1105-1110.
45. Graham, G.G.; Punt, J.; Arora, M.; Day, R.O.; Doogue, M.P.; Duong, J.K.; Furlong, T.J.; Greenfield, J.R.; Greenup, L.C.; Kirkpatrick, C.M.; Ray, J.E.; Timmins, P.; Williams, K.M. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet., 2011, 50(2), 81-98.
46. Thomas, V.H.; Bhattachar, S.; Hitchingham, L.; Zocharski, P.; Naath, M.; Surendran, N.; Stoner, C.L.; El-Kattan, A. The road map to oral bioavailability: an industrial perspective. Expert Opin. Drug Metab. Toxicol., 2006, 2(4), 591-608.
47. Varma, M.V.; Gardner, I.; Steyn, S.J.; Nkansah, P.; Rotter, C.J.; Whitney-Pickett, C.; Zhang, H.; Di, L.; Cram, M.; Fenner, K.S.; El-Kattan, A.F. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery. Mol. Pharm., 2012, 9(5), 1199-1212.
48. Varma, M.V.; Obach, R.S.; Rotter, C.; Miller, H.R.; Chang, G.; Steyn, S.J.; El-Kattan, A.; Troutman, M.D. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. J. Med. Chem., 2010, 53(3), 1098-1108.
49. Varma, M.V.; Ambler, C.M.; Ullah, M.; Rotter, C.J.; Sun, H.; Litchfield, J.; Fenner, K.S.; El-Kattan, A.F. Targeting intestinal transporters for optimizing oral drug absorption. Curr. Drug Metab., 2010, 11(9), 730-742.
50. Tsuji, A.; Tamai, I. Carrier-mediated intestinal transport of drugs. Pharm. Res., 1996, 13(7), 963-977.
51. Cao, X.; Gibbs, S.T.; Fang, L.; Miller, H.A.; Landowski, C.P.; Shin, H.C.; Lennernas, H.; Zhong, Y.; Amidon, G.L.; Yu, L.X.; Sun, D. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res., 2006, 23(8), 1675-1686.
52. Englund, G.; Rorsman, F.; Ronnblom, A.; Karlbom, U.; Lazorova, L.; Grasjo, J.; Kindmark, A.; Artursson, P. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur. J. Pharm. Sci., 2006, 29(3-4), 269-277.
53. Sun, D.; Lennernas, H.; Welage, L.S.; Barnett, J.L.; Landowski, C.P.; Foster, D.; Fleisher, D.; Lee, K.D.; Amidon, G.L. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm. Res., 2002, 19(10), 1400-1416.
54. Falany, C.N. Enzymology of human cytosolic sulfotransferases. FASEB J., 1997, 11(4), 206-216.
55. Paine, M.F.; Hart, H.L.; Ludington, S.S.; Haining, R.L.; Rettie, A.E.; Zeldin, D.C. The human intestinal cytochrome P450 pie. Drug Metab. Dispos., 2006, 34(5), 880-886.
56. Thummel, K.E. Gut instincts: CYP3A4 and intestinal drug metabolism. J. Clin. Invest., 2007, 117(11), 3173-3176.
57. Imai, T.; Taketani, M.; Shii, M.; Hosokawa, M.; Chiba, K. Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine. Drug Metab. Dispos., 2006, 34(10), 1734-1741.
58. Fagerholm, U. Prediction of human pharmacokinetics-biliary and intestinal clearance and enterohepatic circulation. J. Pharm. Pharmacol., 2008, 60(5), 535-542.
59. Gregus, Z.; Klaassen, C.D. Biliary excretion. J. Clin. Pharmacol., 1987, 27(8), 537-541.
60. Varma, M.V.S.; Chang, G.; Lai, Y.; Feng, B.; El-Kattan, A.F.; Litchfield, J.; Goosen, T.C. Physicochemical property space of hepatobiliary transport and computational models for predicting rat biliary excretion. Drug Metab. Dispos., 2012, 40, 1527-1537.
61. Kusuhara, H.; Sugiyama, Y. Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters. Drug Metab. Rev., 2010, 42(3), 539-550.
62. Lai, Y. Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion. Expert Opin. Drug Metab. Toxicol., 2009, 5(10), 1175-1187.
63. Fenner, K.S.; Jones, H.M.; Ullah, M.; Kempshall, S.; Dickins, M.; Lai, Y.; Morgan, P.; Barton, H.A. The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance. Xenobiotica, 2012, 42(1), 28-45.
64. Shitara, Y.; Horie, T.; Sugiyama, Y. Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci., 2006, 27(5), 425-446.
65. Fahrmayr, C.; Fromm, M.F.; Konig, J. Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects. Drug Metab. Rev., 2010, 42(3), 380-401.
66. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 1997, 23(1-3), 3-25.
67. Veber, D.F.; Johnson, S.R.; Cheng, H.Y.; Smith, B.R.; Ward, K.W.; Kopple, K.D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem., 2002, 45(12), 2615-2623.
68. Wenlock, M.C.; Austin, R.P.; Barton, P.; Davis, A.M.; Leeson, P.D. A comparison of physiochemical property profiles of development and marketed oral drugs. J. Med. Chem., 2003, 46(7), 1250-1256.
69. Leeson, P.D.; Davis, A.M. Time-related differences in the physical property profiles of oral drugs. J. Med. Chem., 2004, 47(25), 6338-6348.
70. Leeson, P.D.; Oprea, T.I. In: Drug Design Strategies Quantitative Approaches, Livingstone, D.J.; Davis, A.M.; Eds.; Royal Society of Chemistry: Cambridge, UK, 2012; Vol. 13, pp 35-59.
71. Paolini, G.V.; Shapland, R.H.; van Hoorn, W.P.; Mason, J.S.; Hopkins, A.L. Global mapping of pharmacological space. Nat. Biotechnol., 2006, 24(7), 805-815.
72. Menees, S.B.; Maneerattannaporn, M.; Kim, H.M.; Chey, W.D. The efficacy and safety of rifaximin for the irritable bowel syndrome: A systematic review and meta-analysis. Am. J. Gastroenterol., 2012, 107(1), 28-35.
73. Huang David, B.; DuPont Herbert, L. Rifaximin--a novel antimicrobial for enteric infections. J. Infect., 2005, 50(2), 97-106.
74. Mariani, R.; Maffioli, S.I. Bacterial RNA polymerase inhibitors: an organized overview of their structure, derivatives, biological activity and current clinical development status. Curr. Med. Chem., 2009, 16(4), 430-454.
75. Marchi, E.; Mascellani, G.; Montecchi, L.; Venturini, A.P.; Brufani, M.; Cellai, L. 4-Deoxypyrido[1',2':1,2]imidazo[5,4-c]rifamycin SV derivatives. A new series of semisynthetic rifamycins with high antibacterial activity and low gastroenteric absorption. J. Med. Chem., 1985, 28(7), 960-963.
76. Salix Pharmaceuticals Inc. Xifaxan (rifaximin) tablets, 550 mg NDA 22-554: Briefing document for the Gastrointestinal Drugs Advisory Committee Meeting 23 Feb. 2010. http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Dr ugs/GastrointestinalDrugsAdvisoryCommittee/UCM201081.pdf (Accessed June 26, 2012).
77. Ojetti, V.; Lauritano, E.C.; Barbaro, F.; Migneco, A.; Ainora, M.E.; Fontana, L.; Gabrielli, M.; Gasbarrini, A. Rifaximin pharmacology and clinical implications. Expert Opin. Drug Metab. Toxicol., 2009, 5(6), 675-682.
78. Darkoh, C.; Lichtenberger, L.M.; Ajami, N.; Dial, E.J.; Jiang, Z.-D.; DuPont, H.L. Bile acids improve the antimicrobial effect of rifaximin. Antimicrob. Agents Chemother., 2010, 54(9), 3618-3624.
79. Kulkarni, S.; Dalal, S.K.; Jahagirdar, H.A. Solid dispersion of rifaximin for treatment of microbial infections. WO2011051971, 2011.
80. O'Shea, R.; Moser, H.E. Physicochemical properties of antibacterial compounds: implications for drug discovery. J. Med. Chem., 2008, 51(10), 2871-2878.
81. Agrawal, S.; Panchagnula, R. Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms. Biopharm. Drug Dispos., 2005, 26(8), 321-334.
82. Mariappan, T.T.; Singh, S. Regional gastrointestinal permeability of rifampicin and isoniazid (alone and their combination) in the rat. Int. J. Tuberc. Lung Dis., 2003, 7(8), 797-803.
83. Guimarães, C.R.W.; Mathiowetz, A.M.; Shalaeva, M.; Goetz, G.; Liras, S. Use of 3D properties to characterize beyond rule-of-5 property space for passive permeation. J. Chem. Inf. Model., 2012, 52(4), 882-890.
84. Tedesco, F.; Markham, R.; Gurwith, M.; Christie, D.; Bartlett, J.G. Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet, 1978, 2(8083), 226-228.
85. de Lalla, F.; Nicolin, R.; Rinaldi, E.; Scarpellini, P.; Rigoli, R.; Manfrin, V.; Tramarin, A. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob. Agents Chemother., 1992, 36(10), 2192-2196.
86. Dudley, M.N.; McLaughlin, J.C.; Carrington, G.; Frick, J.; Nightingale, C.H.; Quintiliani, R. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial. Arch. Intern. Med., 1986, 146(6), 1101-1104.
87. Maclayton, D.O.; Eaton-Maxwell, A. Rifaximin for treatment of hepatic encephalopathy. Ann. Pharmacother., 2009, 43(1), 77-84.
88. Graebin, C.S.; Uchoa, F.D.; Bernardes, L.S.C.; Campo, V.L.; Carvalho, I.; Eifler-Lima, V.L. Antiprotozoal agents: an overview. Anti-Infect. Agents Med. Chem., 2009, 8(4), 345-366.
89. Lucas, R.A.; Bowtle, W.J.; Ryden, R. Disposition of vancomycin in healthy volunteers from oral solution and semi-solid matrix capsules. J. Clin. Pharm. Ther., 1987, 12(1), 27-31.
90. Mullane, K.M.; Gorbach, S. Fidaxomicin: first-in-class macro-cyclic antibiotic. Expert Rev. AntiInfect. Ther., 2011, 9(7), 767-777.
91. Fulco, P.; Wenzel, R.P. Ramoplanin: a topical lipoglycodepsi-peptide antibacterial agent. Expert Rev. AntiInfect. Ther., 2006, 4(6), 939-945.
92. Neuman, M. Relationship between chemical structure of antibiotics and pharmacokinetics. Drugs Exp. Clin. Res., 1987, 13(3), 115-124.
93. Schaefer-Korting, M.; Blechschmidt, J.; Korting, H.C. Clinical use of oral nystatin in the prevention of systemic candidiasis in patients at particular risk. Mycoses, 1996, 39(9/10), 329-339.
94. El-Ridy, M.S.; Abdelbary, A.; Essam, T.; Abd El-Salam, R.M.; Aly Kassem, A.A. Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin. Drug Dev. Ind. Pharm., 2011, 37(12), 1491-1508.
95. Yee, H.S.; Fong, N.T. A review of the safety and efficacy of acarbose in diabetes mellitus. Pharmacotherapy, 1996, 16(5), 792-805.
96. Scheen, A.J. Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials. Diabetes Metab., 1998, 24(4), 311-320.
97. 14C]acarbose to rats, dogs and man. Arzneimittelforschung, 1989, 39(10), 1254-1260.
98. Product Monograph, Glucobay, Acarbose, Bayer, Inc. www.bayer.ca/files/GLUCOBAY-PM-ENG-10JUN2010-137275-rev1.pdf (Accessed June 28, 2012).
99. O'Dell, K.M.; Rummel, A.E.; Fang, N.C.; Nguyen, N.N. Linaclotide: a guanylate cyclase type-C agonist for the treatment of constipation-predominant irritable bowel syndrome and chronic constipation. Formulary, 2012, 47, 15-22.
100. Bryant, A.P.; Busby, R.W.; Bartolini, W.P.; Cordero, E.A.; Hannig, G.; Kessler, M.M.; Pierce, C.M.; Solinga, R.M.; Tobin, J.V.; Mahajan-Miklos, S.; Cohen, M.B.; Kurtz, C.B.; Currie, M.G. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci., 2010, 86(19-20), 760-765.
101. Wensel, T.M.; Luthin, D.R. Linaclotide: a novel approach to the treatment of irritable bowel syndrome. Ann. Pharmacother., 2011, 45(12), 1535-1543.
102. Currie, M.G.; Kurtz, C.; Mahajan-Miklos, S.; Busby, R.W.; Fretzen, A.; Geis, S. Effects of single dose administration of MD-1100 on safety, tolerability, exposure, and stool consistency in healthy subjects (abstract 894). Am. J. Gastroenterol., 2005, 100, s328.
103. Evangelista, S. Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome. Curr. Pharm. Des., 2004, 10, 3561-3568.
104. 14C-otilonium bromide in the rat: evidence for selective tropism for large intestine after oral administration. Drug Metab. Dispos., 2000, 28, 643-647.
105. Sutton, J.A.; Kilminster, S.G.; Mould, G.P. The clinical pharmacology of single doses of otilonium bromide in healthy volunteers. Eur. J. Clin. Pharmacol., 1997, 52(5), 365-369.
106. Guerciolini, R. Mode of action of orlistat. Int. J. Obes. (Lond.), 1997, 21(Suppl. 3), S12-S23.
107. Catoira, N.; Nagel, M.; Di Girolamo, G.; Gonzalez, C.D. Pharmacological treatment of obesity in children and adolescents: current status and perspectives. Expert Opin. Pharmacother., 2010, 11(18), 2973-2983.
108. Carriere, F.; Renou, C.; Ransac, S.; Lopez, V.; De Caro, J.; Ferrato, F.; De Caro, A.; Fleury, A.; Sanwald-Ducray, P.; Lengsfeld, H.; Beglinger, C.; Hadvary, P.; Verger, R.; Laugier, R. Inhibition of gastrointestinal lipolysis by orlistat during digestion of test meals in healthy volunteers. Am. J. Physiol., 2001, 281(1, Pt. 1), G16-G28.
109. Zhi, J.; Mulligan, T.E.; Hauptman, J.B. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J. Clin. Pharmacol., 1999, 39(1), 41-46.
110. Zhi, J.; Melia, A.T.; Eggers, H.; Joly, R.; Patel, I.H. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J. Clin. Pharmacol., 1995, 35(11), 1103-1108.
111. Zhi, J.; Melia, A.T.; Funk, C.; Viger-Chougnet, A.; Hopfgartner, G.; Lausecker, B.; Wang, K.; Fulton, J.S.; Gabriel, L.; Mulligan, T.E. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J. Clin. Pharmacol., 1996, 36(11), 1006-1011.
112. Anderson, J.W. Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage. Expert Opin. Pharmacother., 2007, 8(11), 1733-1742.
113. Little, T.J.; Horowitz, M.; Feinle-Bisset, C. Role of cholecystokinin in appetite control and body weight regulation. Obes. Rev., 2005, 6(4), 297-306.
114. Liddle, R.A.; Goldfine, I.D.; Rosen, M.S.; Taplitz, R.A.; Williams, J.A. Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J. Clin. Invest., 1985, 75(4), 1144-1152.
115. Herranz, R. Cholecystokinin antagonists: pharmacological and therapeutic potential. Med. Res. Rev., 2003, 23(5), 559-605.
116. Szewczyk, J.R.; Laudeman, C. CCK1R agonists: a promising target for the pharmacological treatment of obesity. Curr. Top. Med. Chem., 2003, 3(8), 837-854.
117. Sayegh, A.I.; Reeve, J.R., Jr.; Lampley, S.T.; Hart, B.; Gulley, S.; Esdaile, A.R.; Sharma, S.K.; Webb, T.; Williams, C.S.; Pruitt, F. Role for the enteric nervous system in the regulation of satiety via cholecystokinin-8. J. Am. Vet. Med. Assoc., 2005, 226(11), 1809-1816.
118. Sayegh, A.I.; Ritter, R.C. Cholecystokinin activates specific enteric neurons in the rat small intestine. Peptides, 2003, 24(2), 237-244.
119. Sugg, E.E.; Birkemo, L.; Gan, L.S.; Tippin, T.K. Orally active nonpeptide CCK-A agonists. Pharm. Biotechnol., 1998, 11, 507-524.
120. Zhu, C.; Hansen, A.R.; Bateman, T.; Chen, Z.; Holt, T.G.; Hubert, J.A.; Karanam, B.V.; Lee, S.J.; Pan, J.; Qian, S.; Reddy, V.B.; Reitman, M.L.; Strack, A.M.; Tong, V.; Weingarth, D.T.; Wolff, M.S.; MacNeil, D.J.; Weber, A.E.; Duffy, J.L.; Edmondson, S.D. Discovery of imidazole carboxamides as potent and selective CCK1R agonists. Bioorg. Med. Chem. Lett., 2008, 18(15), 4393-4396.
121. Hirst, G.C.; Aquino, C.; Birkemo, L.; Croom, D.K.; Dezube, M.; Dougherty, R.W., Jr.; Ervin, G.N.; Grizzle, M.K.; Henke, B.; James, M.K.; Johnson, M.F.; Momtahen, T.; Queen, K.L.; Sherrill, R.G.; Szewczyk, J.; Willson, T.M.; Sugg, E.E. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): Optimization of the C3 amino substituent. J. Med. Chem., 1996, 39(26), 5236-5245.
122. Aquino, C.J.; Armour, D.R.; Berman, J.M.; Birkemo, L.S.; Carr, R.A.; Croom, D.K.; Dezube, M.; Dougherty, R.W., Jr.; Ervin, G.N.; Grizzle, M.K.; Head, J.E.; Hirst, G.C.; James, M.K.; Johnson, M.F.; Miller, L.J.; Queen, K.L.; Rimele, T.J.; Smith, D.N.; Sugg, E.E. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist trigger. J. Med. Chem., 1996, 39(2), 562-569.
123. Elliott, R.L.; Cameron, K.O.; Chin, J.E.; Bartlett, J.A.; Beretta, E.E.; Chen, Y.; Jardine Pda, S.; Dubins, J.S.; Gillaspy, M.L.; Hargrove, D.M.; Kalgutkar, A.S.; LaFlamme, J.A.; Lame, M.E.; Martin, K.A.; Maurer, T.S.; Nardone, N.A.; Oliver, R.M.; Scott, D.O.; Sun, D.; Swick, A.G.; Trebino, C.E.; Zhang, Y. Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity. Bioorg. Med. Chem. Lett., 2010, 20(22), 6797-6801.
124. Cameron, K.O.; Beretta, E.E.; Chen, Y.; Chu-Moyer, M.; Fernando, D.; Gao, H.; Kohrt, J.; Lavergne, S.; Jardine Pda, S.; Guzman-Perez, A.; Hoth, C.; Perry, D.A.; Hadcock, J.R.; Gautreau, D.; Makowski, M.; Perez, S.; Polivkova, J.; Rogers, L.; Scott, D.O.; Swick, A.G.; Thiede, L.; Trebino, C.E.; Trilles, R.V.; Wilmowski, J.; Zhang, Y. Discovery of new piperidine amide triazolobenzodiazepinones as intestinal-selective CCK1 receptor agonists. Bioorg. Med. Chem. Lett., 2012, 22(8), 2943-2947.
125. Rasenack, N.; Muller, B.W. Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm. Res., 2002, 19, 1894-1900.
126. Friesen, D.T.; Shanker, R.; Crew, M.; Smithey, D.T.; Curatolo, W.J.; Nightingale, J.A. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Mol. Pharm., 2008, 5(6), 1003-1019.
127. Curatolo, W.; Nightingale, J.A.; Herbig, S.M. Utility of hydroxypropylmethylcellulose acetate succinate (HPMCAS) for initiation and maintenance of drug supersaturation in the GI milieu. Pharm. Res., 2009, 26(6), 1419-1431.
128. Bodor, N.; Buchwald, P. Soft drug design: general principles and recent applications. Med. Res. Rev., 2000, 20(1), 58-101.
129. Erhardt, P.W.; Reese, M.D. In: Prodrugs and Targeted Delivery: Towards Better ADME Properties, Rautio, J.; Ed.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, 2011; Vol. 47, pp 385-413.
130. Cuchel, M.; Bloedon, L.T.; Szapary, P.O.; Kolansky, D.M.; Wolfe, M.L.; Sarkis, A.; Millar, J.S.; Ikewaki, K.; Siegelman, E.S.; Gregg, R.E.; Rader, D.J. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med., 2007, 356(2), 148-156.
131. Meerpoel, L.; Viellevoye, M. Preparation of piperidinyl-, pipera-zinylcarboxamides as lipid lowering agents. WO2002081460, 2002.
132. Mera, Y.; Odani, N.; Kawai, T.; Hata, T.; Suzuki, M.; Hagiwara, A.; Katsushima, T.; Kakutani, M. Pharmacological characterization of diethyl-2-({3-dimethylcarbamoyl-4-[(4'-trifluoromethylbiphen-yl-2-carbonyl)amino]phenyl}acetyloxymethyl)-2-phenylma-lonate (JTT-130), an intestine-specific inhibitor of microsomal triglyceride transfer protein. J. Pharmacol. Exp. Ther., 2011, 336, 321-327.
133. Lacy, B.E.; Chey, W.D. Lubiprostone: chronic constipation and irritable bowel syndrome with constipation. Expert Opin. Pharmacother., 2009, 10(1), 143-152.
134. Ao, M.; Venkatasubramanian, J.; Boonkaewwan, C.; Ganesan, N.; Syed, A.; Benya, R.V.; Rao, M.C. Lubiprostone activates Cl-secretion via cAMP signaling and increases membrane CFTR in the human colon carcinoma cell line, T84. Dig. Dis. Sci., 2011, 56(2), 339-351.
135. Lacy, B.E.; Campbell Levy, L. Lubiprostone: A chloride channel activator. J. Clin. Gastroenterol., 2007, 41(4), 345-351.
136. Lacy, B.E.; Levy, L.C. Lubiprostone: a novel treatment for chronic constipation. Clin. Interv. Aging, 2008, 3(2), 357-364.
137. Lipecka, J.; Bali, M.; Thomas, A.; Fanen, P.; Edelman, A.; Fritsch, J. Distribution of ClC-2 chloride channel in rat and human epithelial tissues. Am. J. Physiol., 2002, 282(4, Pt. 1), C805-C816.
138. Amitiza complete prescribing information http://www.amitiza.com/ (Accessed Feb 7, 2012).
139. Holzer, P. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci. Lett., 2004, 361(1-3), 192-195.
140. Fishman, J.; Roffwarg, H.; Hellman, L. Disposition of naloxone-7,8-3H in normal and narcotic-dependent men. J. Pharmacol. Exp. Ther., 1973, 187, 575-580.
141. Abarca, F.M.; Saclarides, T.J.; Brand, M.I. A review of the treatment of opioid-induced constipation with methylnaltrexone bromide. Clin. Med. Insights: Ther., 2010, 2, 53-60.
142. Kotake, A.N.; Kuwahara, S.K.; Burton, E.; McCoy, C.E.; Goldberg, L.I. Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans. Xenobiotica, 1989, 19, 1247-1254.
143. Chandrasekaran, A.; Tong, Z.; Li, H.; Erve, J.C.; DeMaio, W.; Goljer, I.; McConnell, O.; Rotshteyn, Y.; Hultin, T.; Talaat, R.; Scatina, J. Metabolism of intravenous methylnaltrexone in mice, rats, dogs, and humans. Drug Metab. Dispos., 2010, 38(4), 606-616.
144. Delaney, C.P.; Yasothan, U.; Kirkpatrick, P. Alvimopan. Nat. Rev. Drug Discov., 2008, 7(9), 727-728.
145. Zimmerman, D.M.; Gidda, J.S.; Cantrell, B.E.; Schoepp, D.D.; Johnson, B.G.; Leander, J.D. Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders. J. Med. Chem., 1994, 37(15), 2262-2265.
146. Foley, D.W.; Rajamanickam, J.; Bailey, P.D.; Meredith, D. Bioavailability through PepT1: the role of computer modelling in intelligent drug design. Curr. Comput. Aided Drug Des., 6(1), 68-78.
147. Meredith, D.; Price, R.A. Molecular modeling of PepT1--towards a structure. J. Membr. Biol., 2006, 213(2), 79-88.
148. +/peptide symporter. Eur. J. Biochem., 1999, 266(2), 502-508.
149. Soul-Lawton, J.; Seaber, E.; On, N.; Wootton, R.; Rolan, P.; Posner, J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob. Agents Chemother., 1995, 39(12), 2759-2764.
150. Bueno, A.B.; Collado, I.; de Dios, A.; Dominguez, C.; Martin, J.A.; Martin, L.M.; Martinez-Grau, M.A.; Montero, C.; Pedregal, C.; Catlow, J.; Coffey, D.S.; Clay, M.P.; Dantzig, A.H.; Lindstrom, T.; Monn, J.A.; Jiang, H.; Schoepp, D.D.; Stratford, R.E.; Tabas, L.B.; Tizzano, J.P.; Wright, R.A.; Herin, M.F. Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist. J. Med. Chem., 2005, 48(16), 5305-5320.
151. Varma, M.V.; Eriksson, A.H.; Sawada, G.; Pak, Y.A.; Perkins, E.J.; Zimmerman, C.L. Transepithelial transport of the group II metabotropic glutamate 2/3 receptor agonist (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) and its prodrug (1S,2S,5R,6S)-2-[(2'S)-(2'-amino)propionyl]aminobicyclo [3.1.0]hexane-2,6-dicarboxylate (LY544344). Drug Metab. Dispos., 2009, 37(1), 211-220.
152. Rubio-Aliaga, I.; Daniel, H. Peptide transporters and their roles in physiological processes and drug disposition. Xenobiotica, 2008, 38(7-8), 1022-1042.
153. Rubio-Aliaga, I.; Daniel, H. Mammalian peptide transporters as targets for drug delivery. Trends Pharmacol. Sci., 2002, 23(9), 434-440.
154. Kullak-Ublick, G.A.; Ismair, M.G.; Stieger, B.; Landmann, L.; Huber, R.; Pizzagalli, F.; Fattinger, K.; Meier, P.J.; Hagenbuch, B. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology, 2001, 120(2), 525-533.
155. Sai, Y.; Kaneko, Y.; Ito, S.; Mitsuoka, K.; Kato, Y.; Tamai, I.; Artursson, P.; Tsuji, A. Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab. Dispos., 2006, 34(8), 1423-1431.
156. Tamai, I.; Nezu, J.; Uchino, H.; Sai, Y.; Oku, A.; Shimane, M.; Tsuji, A. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun., 2000, 273(1), 251-260.
157. Kobayashi, D.; Nozawa, T.; Imai, K.; Nezu, J.; Tsuji, A.; Tamai, I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J. Pharmacol. Exp. Ther., 2003, 306(2), 703-708.
158. Nozawa, T.; Imai, K.; Nezu, J.; Tsuji, A.; Tamai, I. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J. Pharmacol. Exp. Ther., 2004, 308(2), 438-445.
159. Grube, M.; Kock, K.; Karner, S.; Reuther, S.; Ritter, C.A.; Jedlitschky, G.; Kroemer, H.K. Modification of OATP2B1-mediated transport by steroid hormones. Mol. Pharmacol., 2006, 70(5), 1735-1741.
160. Grube, M.; Kock, K.; Oswald, S.; Draber, K.; Meissner, K.; Eckel, L.; Bohm, M.; Felix, S.B.; Vogelgesang, S.; Jedlitschky, G.; Siegmund, W.; Warzok, R.; Kroemer, H.K. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin. Pharmacol Ther., 2006, 80(6), 607-620.
161. Satoh, H.; Yamashita, F.; Tsujimoto, M.; Murakami, H.; Koyabu, N.; Ohtani, H.; Sawada, Y. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab. Dispos., 2005, 33(4), 518-523.
162. Varma, M.V.; Rotter, C.J.; Chupka, J.; Whalen, K.M.; Duignan, D.B.; Feng, B.; Litchfield, J.; Goosen, T.C.; El-Kattan, A.F. pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol. Pharm., 2011, 8(4), 1303-1313.
163. Juel, C. Lactate-proton cotransport in skeletal muscle. Physiol. Rev., 1997, 77(2), 321-358.
164. Halestrap, A.P.; Price, NT. The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem. J., 1999, 343(Pt 2), 281-299.
165. Enerson, B.E.; Drewes, L.R. Molecular features, regulation, and function of monocarboxylate transporters: implications for drug delivery. J. Pharm. Sci., 2003, 92(8), 1531-1544.
166. Halestrap, A.P.; Meredith, D. The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflügers Archiv, 2004, 447(5), 619-628.
167. Li, Y.-H.; Ito, K.; Tsuda, Y.; Kohda, R.; Yamada, H.; Itoh, T. Mechanism of intestinal absorption of an orally active Î-lactam prodrug: Uptake and transport of carindacillin in caco-2 cells. J. Pharmacol. Exp. Ther., 1999, 290(3), 958-964.
168. Cundy, K.C.; Branch, R.; Chernov-Rogan, T.; Dias, T.; Estrada, T.o.; Hold, K.; Koller, K.; Liu, X.; Mann, A.; Panuwat, M.; Raillard, S.P.; Upadhyay, S.; Wu, Q.Q.; Xiang, J.-N.; Yan, H.; Zerangue, N; Zhou, C.X.; Barrett, R.W.; Gallop, M.A. XP13512 [(±)-1-([(a-isobutanoyloxyethoxy)carbonyl]aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters J. Pharmacol. Exp. Ther., 2004, 311(1), 315-323.
169. Adibi, SA. The oligopeptide transporter (Pept-1) in human intestine: biology and function. Gastroenterology, 1997, 113(1), 332-340.
170. Serrano-Wu, M.H.; Coppola, G.M.; Gong, Y.; Neubert, A.D.; Chatelain, R.; Clairmont, K.B.; Commerford, R.; Cosker, T.; Daniels, T.; Hou, Y.; Jain, M.; Juedes, M.; Li, L.; Mullarkey, T.; Rocheford, E.; Sung, M.J.; Tyler, A.; Yang, Q.; Yoon, T.; Hubbard, B.K. Intestinally targeted diacylglycerol acyltransferase 1 (DGAT1) inhibitors robustly suppress postprandial triglycerides. ACS Med. Chem. Lett, 2012, 3, 411-415.
171. Davis, H.R.; Veltri, E.P. Zetia: inhibition of Niemann-Pick C1 like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J. Atheroscler. Thromb., 2007,14(3), 99-108.
172. Kosoglou, T.; Statkevich, P.; Johnson-Levonas, A.O.; Paolini, J.F.; Bergman, A J.; Alton, K.B. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin. Pharmacokinet., 2005, 44(5), 467-494.
173. Pramfalk, C; Jiang, Z.-Y.; Parini, P. Hepatic Niemann-Pick C1-like 1. Curr. Opin. Lipidol, 2011, 22(3), 225-230.
174. Martinez, E.J.; Talley, J.J. Preparation of quaternary salt derivatives of 1,4-diphenylazetidin-2-ones for the treatment of hypercholesterolemia. WO2005021495, 2005.
175. Talley, J.J.; Martinez, E.J. Processes for production of dipheny-lylazetidin-2-ones and related compounds. WO2008057948, 2008.
176. Jaehne, G.; Heuer, H.O.; Schaefer, H.-L.; Frick, W.; Lindenschmidt, A.; Glombik, H.; Flohr, S.; Theis, S.; Kramer, W. In: Canosimibe: Design, synthesis, and in vivo activity of a nonsystemic inhibitor of cholesterol absorption, Abstracts of Papers, 239th ACS National Meeting, San Francisco, CA, March 21-25, 2010; American Chemical Society: Washington, D.C., 2010; MEDI-283.
177. Wollmann, T.A.; Junker, B.; Otto, B.; Maier, C.-J. Preparation of canosimibe. WO2009112203, 2009.
178. National Center for Advancing Translational Sciences-AVE5530 (canosimibe) Summary. www.ncats.nih.gov/files/AVE5530.pdf (Accessed July 18, 2012).
179. Rautio, J. In: Prodrugs and Targeted Delivery: Towards Better ADME Properties, Rautio, J.; Ed.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, 2010; pp 1-30.
180. Wu, K.-M. A new classification of prodrugs: Regulatory perspectives. Pharmaceuticals, 2009, 2(3), 77-81.
181. Dhaneshwar, S.S.; Vadnerkar, G. Rational design and development of colon-specific prodrugs. Curr. Top. Med. Chem., 2011, 11(18), 2318-2345.
182. Hirayama, F.; Uekama, K. In: Prodrugs, Stella, V.J.; Borchardt, R.T.; Hageman, M.J.; Oliyai, R.; Maag, H.; Tilley, J.W.; Eds.; Springer: New York, 2007; pp 683-699.
183. Klotz, U.; Maier, K.; Fischer, C.; Heinkel, K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N. Engl. J. Med., 1980, 303(26), 1499-1502.
184. +)-ATPase by proton pump inhibitors. J. Am. Chem. Soc., 2004, 126(25), 7800-7811.
185. Fernandez-Martos, C.; Nogue, M.; Cejas, P.; Moreno-Garcia, V.; Machancoses, A.H.; Feliu, J. The role of capecitabine in locally advanced rectal cancer treatment: an update. Drugs, 2012, 72(8), 1057-1073.
186. Skanji, R.; Andrieux, K.; Lalanne, M.; Caron, J.; Bourgaux, C.; Degrouard, J.; Brisset, F.; Gueutin, C.; Chacun, H.; Dereuddre-Bosquet, N.; Paci, A.; Vassal, G.; Bauduin, L.; Garcia-Argote, S.; Rousseau, B.; Clayette, P.; Desmaele, D.; Couvreur, P. A new nanomedicine based on didanosine glycerolipidic prodrug enhances the long term accumulation of drug in a HIV sanctuary. Int. J. Pharm., 2011, 414(1-2), 285-297.
187. Chourasia, M.K.; Jain, S.K. Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Pharm. Sci., 2003, 6(1), 33-66.
188. Hughes, I.W. First-line treatment in acute non-dysenteric diarrhoea: clinical comparison of loperamide oxide, loperamide and placebo. UK Janssen Research Group of General Practitioners. Br. J. Clin. Pract., 1995, 49(4), 181-185.
189. Scheline, R.R. Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol. Rev., 1973, 25(4), 451-523.
190. Rafii, F.; Franklin, W.; Cerniglia, C.E. Azoreductase activity of anaerobic bacteria isolated from human intestinal microflora. Appl. Environ. Microbiol., 1990, 56(7), 2146-2151.
191. Friend, D.R.; Chang, G.W. A colon-specific drug-delivery system based on drug glycosides and the glycosidases of colonic bacteria. J. Med. Chem., 1984, 27(3), 2666.
192. Hawksworth, G.; Drasar, B.S.; Hill, M.J. Intestinal bacteria and the hydrolysis of glycosidic bonds. J. Med. Microbiol., 1971, 4(4), 451-459.
193. Nolen, H., 3rd; Fedorak, R.N.; Friend, D.R. Budesonide-beta-D-glucuronide: a potential prodrug for treatment of ulcerative colitis. J. Pharm. Sci., 1995, 84(6), 677-681.
194. Nolen, H.W., 3rd; Friend, D.R. Menthol-beta-D-glucuronide: a potential prodrug for treatment of the irritable bowel syndrome. Pharm. Res., 1994, 11(12), 1707-1711.
195. Laine, K.; Huttunen, K. In: Prodrugs and Targeted Delivery: Towards Better ADME Properties, Rautio, J.; Ed.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, 2010; pp 231-252.
196. Boyer, S.H.; Jiang, H.; Jacintho, J.D.; Reddy, M.V.; Li, H.; Li, W.; Godwin, J.L.; Schulz, W.G.; Cable, E.E.; Hou, J.; Wu, R.; Fujitaki, J.M.; Hecker, S.J.; Erion, M.D. Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs. J. Med. Chem., 2008, 51(22), 7075-7093.
197. Boddu, S.H.S.; Kwatra, D.; Mitra, A.K. In: Oral Bioavailability: Basic Principles, Advanced Concepts, and Applications, Hu, M.; Li, X.; Eds.; John Wiley & Sons, Inc.: Hoboken, New Jersey, 2011; pp 355-369.
198. Roldo, M.; Barbu, E.; Brown, J.F.; Laight, D.W.; Smart, J.D.; Tsibouklis, J. Azo compounds in colon-specific drug delivery. Expert Opin. Drug Deliv., 2007, 4(5), 547-560.
199. Kam, L.; Cohen, H.; Dooley, C.; Rubin, P.; Orchard, J. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults. Am. J. Gastroenterol., 1996, 91(7), 1338-1342.
200. Andus, T.; Kocjan, A.; Muser, M.; Baranovsky, A.; Mikhailova, T.L.; Zvyagintseva, T.D.; Dorofeyev, A.E.; Lozynskyy, Y.S.; Cascorbi, I.; Stolte, M.; Vieth, M.; Dilger, K.; Mohrbacher, R.; Greinwald, R. Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflamm. Bowel Dis., 2010, 16(11), 1947-1956.
201. Fischer, C.; Maier, K.; Stumpf, E.; von Gaisberg, U.; Klotz, U. Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man. Eur. J. Clin. Pharmacol., 1983, 25(4), 511-515.
202. Azadkhan, A.K.; Truelove, S.C.; Aronson, J.K. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br. J. Clin. Pharmacol., 1982, 13(4), 523-528.
203. Klotz, U. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin. Pharmacokinet., 1985, 10(4), 285-302.
204. Sandborn, W.J.; Hanauer, S.B. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment. Pharmacol. Ther., 2003, 17(1), 29-42.
205. Levine, W.G.; Raza, H. Mechanism of azoreduction of dimethylaminoazobenzene by rat liver NADPH-cytochrome P-450 reductase and partially purified cytochrome P-450. Oxygen and carbon monoxide sensitivity and stimulation by FAD and FMN. Drug Metab. Dispos., 1988, 16(3), 441-448.
206. Staerk Laursen, L.; Stokholm, M.; Bukhave, K.; Rask-Madsen, J.; Lauritsen, K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut, 1990, 31(11), 1271-1276.
207. Christensen, L.A. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man. Dan. Med. Bull., 2000, 47(1), 20-41.
208. Cheng, G.; An, F.; Zou, M.J.; Sun, J.; Hao, X.H.; He, Y.X. Time-and pH-dependent colon-specific drug delivery for orally administered diclofenac sodium and 5-aminosalicylic acid. World J. Gastroenterol., 2004, 10(12), 1769-1774.
209. Ryde, E.M.; Ahnfelt, N.O. The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food. Eur. J. Clin. Pharmacol., 1988, 34(5), 481-488.
210. Kane, S.V.; Bjorkman, D.J. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. Rev. Gastroenterol. Disord., 2003, 3(4), 210-218.
211. Nikfar, S.; Rahimi, R.; Rezaie, A.; Abdollahi, M. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig. Dis. Sci., 2009, 54(6), 1157-1170.
212. Lavrijsen, K.; van Dyck, D.; van Houdt, J.; Hendrickx, J.; Monbaliu, J.; Woestenborghs, R.; Meuldermans, W.; Heykants, J. Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humans. Drug Metab. Dispos., 1995, 23(3), 354-362.
213. Kamali, F.; Adriaens, L.; Huang, M.L.; Woestenborghs, R.; Emanuel, M.; Rawlins, M.D. Dose proportionality study of loperamide following oral administration of loperamide oxide. Eur. J. Clin. Pharmacol., 1992, 42(6), 693-694.
214. Patrick, J.E.; Kosoglou, T.; Stauber, K.L.; Alton, K.B.; Maxwell, S.E.; Zhu, Y.; Statkevich, P.; Iannucci, R.; Chowdhury, S.; Affrime, M.; Cayen, M.N. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab. Dispos., 2002, 30(4), 430-437.
215. Friend, D.R.; Chang, G.W. Drug glycosides: potential prodrugs for colon-specific drug delivery. J. Med. Chem., 1985, 28(1), 51-57.
216. Tozer, T.N.; Rigod, J.; McLeod, A.D.; Gungon, R.; Hoag, M.K.; Friend, D.R. Colon-specific delivery of dexamethasone from a glucoside prodrug in the guinea pig. Pharm. Res., 1991, 8(4), 445-454.
217. Jung, Y.J.; Lee, J.S.; Kim, Y.M. Synthesis and in vitro/in vivo evaluation of 5-aminosalicyl-glycine as a colon-specific prodrug of 5-aminosalicylic acid. J. Pharm. Sci., 2000, 89(5), 594-602.
218. Yano, H.; Hirayama, F.; Arima, H.; Uekama, K. Prednisolone-appended alpha-cyclodextrin: alleviation of systemic adverse effect of prednisolone after intracolonic administration in 2,4,6-trinitrobenzenesulfonic acid-induced colitis rats. J. Pharm. Sci., 2001, 90(12), 2103-2112.
219. Hemenway, J.N. In: Prodrugs, Stella, V.J.; Borchardt, R.T.; Hageman, M.J.; Oliyai, R.; Maag, H.; Tilley, J.W.; Eds.; Springer: New York, 2007; pp 1313-1321.
220. Lindberg, P.; Nordberg, P.; Alminger, T.; Brandstrom, A.; Wallmark, B. The mechanism of action of the gastric acid secretion inhibitor omeprazole. J. Med. Chem., 1986, 29(8), 1327-1329.
221. Clissold, S.P.; Campoli-Richards, D.M. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs, 1986, 32(1), 15-47.
222. Waterman, K.C. A critical review of gastric retentive controlled drug delivery. Pharm. Dev. Technol., 2007, 12(1), 1-10.
223. Klausner, E.A.; Lavy, E.; Friedman, M.; Hoffman, A. Expandable gastroretentive dosage forms. J. Control. Release, 2003, 90(2), 143-162.
224. Kagan, L.; Lapidot, N.; Afargan, M.; Kirmayer, D.; Moor, E.; Mardor, Y.; Friedman, M.; Hoffman, A. Gastroretentive Accordion Pill: Enhancement of riboflavin bioavailability in humans. J. Control. Release, 2006, 113(3), 208-215.
225. Gusler, G.; Gorsline, J.; Levy, G.; Zhang, S.Z.; Weston, I.E.; Naret, D.; Berner, B. Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers. J. Clin. Pharmacol., 2001, 41(6), 655-661.
226. Berner, B.; Cowles, V.E. Case studies in swelling polymeric gastric retentive tablets. Expert Opin. Drug Deliv., 2006, 3(4), 541-548.
227. Arora, S.; Ali, J.; Ahuja, A.; Khar, R.K.; Baboota, S. Floating drug delivery systems: a review. AAPS PharmSciTech, 2005, 6(3), E372-390.
228. Singh, B.N. Modified-release solid formulations for colonic delivery. Recent Pat. Drug Deliv. Formul., 2007, 1(1), 53-63.
229. Basit, A.W. Advances in colonic drug delivery. Drugs, 2005, 65(14), 1991-2007.
230. Sinha, V.R.; Kumria, R. Polysaccharides in colon-specific drug delivery. Int. J. Pharm., 2001, 224(1-2), 19-38.
231. Shamut, M.A. The role of the gastrointestinal microflora in the metabolism of drugs. Int. J. Pharm., 1993, 97(1-3), 1-13.
232. Philip, A.K.; Philip, B. Colon targeted drug delivery systems: a review on primary and novel approaches. Oman Med. J., 2010, 25(2), 79-87.
233. Yang, L.; Chu, J.S.; Fix, J.A. Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int. J. Pharm., 2002, 235(1-2), 1-15.
234. Takaya, T.; Ikeda, C.; Imagawa, N.; Niwa, K.; Takada, K. Development of a colon delivery capsule and the pharmacological activity of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in beagle dogs. J. Pharm. Pharmacol., 1995, 47(6), 474-478.
235. Omidian, H.; Fesharaki, S.; Park, K. In: Controlled Release in Oral Drug Delivery, Wilson, C.G.; Crowley, P.J.; Eds.; Springer US: New York, 2011; pp 109-129.
236. Tebrean, B.; Crisan, S.; Rarnovan, I.G.; Crisan, T.E. Novel drug delivery systems-method review. Acta Electrotehnica, 2011, 52(1), 49-55.
237. Twomey, K.; Marchesi, J.R. Swallowable capsule technology: current perspectives and future directions. Endoscopy, 2009, 41(4), 357-362.
238. Lambkin, I.; Pinilla, C. Targeting approaches to oral drug delivery. Expert Opin. Biol. Ther., 2002, 2(1), 67-73.
239. Alex, M.R.A.; Chacko, A.J.; Jose, S.; Souto, E.B. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur. J. Pharm. Sci., 2011, 42(1-2), 11-18.
240. Santangelo, R.; Paderu, P.; Delmas, G.; Chen, Z.W.; Mannino, R.; Zarif, L.; Perlin, D.S. Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis. Antimicrob. Agents Chemother., 2000, 44(9), 2356-2360.
241. Bracho, G.; Lastre, M.; del Campo, J.; Zayas, C.; Gonzalez, D.; Gil, D.; Acevedo, R.; Taboada, C.; Solis, R.L.; Perez, O. Proteoliposome derived cochleate as novel adjuvant. Vaccine, 2006, 24 Suppl 2, S2-30-31.
242. Fan, J.; Chen, S.; Chow, E.C.; Pang, K.S. PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. Curr. Drug Metab., 2010, 11(9), 743-761.
243. Nestorov, I. Whole-body physiologically based pharmacokinetic models. Expert Opin. Drug Metab. Toxicol., 2007, 3(2), 235-249.